3SOF

neol moving up again..no news

can't find any news on this one,but it keeps on climbing..ant thoughts?

wow!!  -70% as of now!!


NeoPharm drug misses goal in brain-cancer trial
NEW YORK, Dec 11 (Reuters) - NeoPharm Inc. (NEOL.O: Quote, Profile , Research) said on Monday that its experimental drug, cintredekin besudotox, failed to meet the efficacy goal in a late-stage study for brain cancer.

The company said it would work with its scientific advisers and regulators to determine the next steps.

NeoPharm upgraded to "hold"

Monday, December 11, 2006 3:21:54 PM ET
Brean Murray, Carret & Co

NEW YORK, December 11 (newratings.com) - Analysts at Brean Murray upgrade NeoPharm Inc (NEOL.NAS) from "sell" to "hold."

christmas update incl MACD crossing, bottom fishing in 2007 ?

1)
NeoPharm downgraded to "market outperform" - update
Tuesday, December 12, 2006 1:30:21 PM ET
JMP Securities
NEW YORK, December 12 (newratings.com) - Analysts at JMP Securities downgrade NeoPharm Inc (NEOL.NAS) from "strong buy" to "market outperform," while raising their estimates for the company. The target price has been reduced from $19 to $6.
In a research note published yesterday, the analysts mention that the company's Phase III PRECISE trial has failed to meet its primary endpoint. The downgrade in the rating reflects the undervalued NeoLipid programme and the recent sell-off in NeoPharm's stock, the analysts add. The EPS estimate for 2007 has been raised from -$1.32 to -$0.72.

2)
NeoPharm downgraded to "neutral"
Tuesday, December 12, 2006 3:34:47 AM ET
First Albany
NEW YORK, December 12 (newratings.com) - In a research note published yesterday, analysts at First Albany downgrade NeoPharm (NEOL.NAS) from "buy" to "neutral."

3)
NeoPharm "neutral," target price reduced
Tuesday, December 12, 2006 7:46:37 AM ET
Robert W. Baird
NEW YORK, December 12 (newratings.com) - Analysts at Robert W Baird reiterate their "neutral" rating on NeoPharm Inc (NEOL.NAS), while reducing their estimates for the company.
The target price has been reduced from $8 to $2.
In a research note published yesterday, the analysts mention that the company has announced that its Phase 3 PRECISE trial for cintredekin besudotox (IL-13) has failed to show better efficacy than Gliadel. NeoPharm is now left with few value drivers in its pipeline, with the Neolipid development programme having put on the backburner, the analysts say. The EPS estimates for 2007, 2008 and 2009 have been reduced from -$1.45 to -$0.82, from -$0.63 to -$0.82 and from $0.50 to -$0.81, respectively.

4)
NeoPharm downgraded to "reduce"
Tuesday, December 12, 2006 8:34:13 AM ET
UBS
NEW YORK, December 12 (newratings.com) - Analysts at UBS downgrade NeoPharm Inc (NEOL.NAS) from "neutral" to "reduce."

5)
NeoPharm cuts 20 percent of work force
Fri Dec 22, 2006 5:16 PM ET
LOS ANGELES, Dec 22 (Reuters) - Drug developer NeoPharm Inc. <NEOL.O> said on Friday that it has completed a restructuring which reduced its work force by 14 jobs, or about 20 percent.
The company estimated costs associated with termination benefits at about $300,000 and said the cuts will yield 2007 cost savings of about $1.5 million over 2006.

This is what happen when you buy shitty company.  Welcome to Vega.....

Volume coming in out of nowhere, no news, in at 2.05 for a trade.

While reading the latest issue of Journal of Clinical Oncology (most prestigious oncology journal) published today, I stumbled upon a report describing the effect of Cintredekin Besudotox (IL13-PE38QQR) on Recurrent Malignant Glioma published by UCSF group. This happens to be the drug being developed by NEOL. They conclude that Cintredekin appears to have a favorable effect on patients with relapsed glioblastoma..
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17327604&query_hl=3&itool=pubmed_docsum
I think it explains recent increased activity in this stock and together with todays news that NEOL will discuss its 2006 results and update on Cintredekin on March the 14th it could cause a nice speculative rise  . I bought this morning. Let's see what happens :-).

I posted the same message on NEOL yahoo board and on Investorshub.com... A little private pump action 
better link for the paper: http://www.jco.org/cgi/content/abstract/25/7/837 . I could get fulltext version if anybody would be interested in :-).